These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review.
    Author: Fragoso YD, Adoni T, Alves-Leon SV, Azambuja ND, Barreira AA, Brooks JB, Carneiro DS, Carvalho MJ, Claudino R, Comini-Frota ER, Domingues RB, Finkelzstejn A, Gama PD, Giacomo MC, Gomes S, Goncalves MV, Grzesiuk AK, Kaimen-Maciel DR, Mendes MF, Morales NM, Morales RR, Muniz A, Papais-Alvarenga RM, Parolin MK, Ribeiro SB, Ruocco HH, Siquineli F, Tosta ED.
    Journal: CNS Drugs; 2013 Nov; 27(11):955-61. PubMed ID: 24114585.
    Abstract:
    INTRODUCTION: Multiple sclerosis (MS) mainly affects women of fertile age. To date, the only recommendation for women with MS intending to become pregnant is to stop all treatment. This recommendation reflects the concerns about the effects of disease-modifying drugs (DMDs) on the offspring. The objective of the present study was to assess the potential long-term effects of maternal exposure to DMDs on the offspring. METHOD: This was a retrospective study revising medical data on the offspring of women with MS. These women now have children aged at least 1 year and include a group of patients that were not exposed to any DMDs for at least 3 months prior to pregnancy and during the whole gestation (control group). Another group of patients had at least 2 weeks of exposure to DMDs, mainly to interferon beta or glatiramer acetate RESULTS: The women with MS participating in this study have children currently aged, on average, 6.6 years (range 1-39 years). There was no pattern of drug-related adverse events or complications in the children whose mothers were exposed to DMDs. No specific long-term adverse events were observed in the offspring of women with MS who were exposed to drugs during pregnancy. The profile of relevant diagnoses in their children was similar to that of children whose mothers had not been exposed to DMDs. CONCLUSIONS: The present retrospective study did not show a specific profile of long-term deleterious drug effects on children born from mothers who were exposed to drugs for MS treatment.
    [Abstract] [Full Text] [Related] [New Search]